References
1. American Psychiatric Association. Diagnostic and statistical manual. 4th ed. Washington, DC: American Psychiatric Press, 1994
2. FeinsteinA, FeinsteinK J. Depression associated with multiple sclerosis: looking beyond diagnosis to symptom expression. J Affect Disord 2001;66:193–8
3. MindenS L, OravJ, ReichP. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426–34
4. JoffeR T, LippertG P, GrayT A, SawaG, HorvathZ. Mood disorder and multiple sclerosis. Arch Neurol 1987;44:376–8
5. SadovnikA N, RemickR A, AllenJ, et al. Depression and multiple sclerosis. Neurology 1996;46:628–32
6. PattenS B, BeckC A, WilliamsJ V A, BarbuiC, MetzL M. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61:1524–7
7. ZigmondA S, SnaithR P. The Hospital and Anxiety Depression Scale. Acta Psychiatr Scand 1983;67:361–70
8. BeckA T, SteerR A, BrownG K. BDI-Fast Screen for Medical Patients manual. San Antonio, TX: The Psychological Corporation, 2000.
9. BenedictR H, FishmanI, McClellanM M, BakshiR, Weinstock-GuttmanB. Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler 2003;9:393–6
10. FeinsteinA, O'ConnorP, GrayT, FeinsteinK. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999;5:323–6
11. QuesnelS, FeinsteinA. Multiple sclerosis and alcohol: a study of problem drinking. Mult Scler 2004;10:197–201
12. KorostilM, FeinsteinA. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007;13:67–72
13. StenagerE N, StenagerE, Koch-HendriksonN, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542–5
14. FeinsteinA. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59:674–8
15. PattenS B, MetzL M, ReimerM A. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000;6:115–20
16. SchifferR B, CaineE D, BamfordK A, LevyS. Depressive episodes in patients with multiple sclerosis. Am J Psychiatry 1983;140:1498–500
17. PujolJ, BelloJ, DeusJ, Marti-VilaltaJ L, CapdevilaA. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997;49:1105–10
18. BergD, SupprianT, ThomaeJ, et al. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler 2000;6:156–62
19. BakshiR, CzarneckiD, ShaikhZ A, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. NeuroReport 2000;11:1153–8
20. FeinsteinA, RoyP, LobaughN, FeinsteinK J, O'ConnorP. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62:586–90
21. MoradzadehL, FeinsteinA, LobaughN, RamirezJ. Multiple sclerosis and depression: a diffusion MRI study. (Abstract.)J Neuropsychiatry Clin Neurosci 2007;19:232
22. LynchS G, KroenckeD C, DenneyD R. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping and hope. Mult Scler 2001;7:411–16
23. MohrD C, GoodkinD E, GattoN, van der WendeJ. Depression, coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997;3:254–8
24. PakenhamK I. Adjustment to multiple sclerosis: application of a stress coping model. Health Psychol 1999;18:383–92
25. ShnekZ M, FoleyF W, LaRoccaN G, et al. Helplessness, self-efficacy, cognitive distortions, and depression in multiple sclerosis and spinal cord injury. Ann Behav Med 1997;19:287–94
26. MayburyC P, BrewinC R. Social relationships, knowledge and adjustment to multiple sclerosis. J Neurol Neurosurg Psychiatry 1984;47:372–6
27. VossW D, ArnettP A, HigginsonC I, et al. Contributing factors to depressed mood in multiple sclerosis. Arch Clin Neuropsychol 2002;17:103–15
28. SchifferR B, WinemanN M. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990;147:1493–7
29. ScottT F, NussbaumP, McConnellH, BrillP. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995;17:421–2
30. BarakY, UrE, ArchironA. Moclobemide treatment in multiple sclerosis patients with co-morbid depression: an open label safety trial. J Neuropsychiatry Clin Neurosci 1999;11:271–3
31. MohrD C, BoudewynA C, GoodkinD, BostromA, EpsteinL. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group therapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69:942–9
32. MohrD C, LikoskyW, BertagnoliA, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol 2000;68:356–61
33. MattingleyG, BakerK, ZorumskiC F, FigielG S. Multiple sclerosis and ECT: possible value of gadolinium enhanced magnetic resonance scans for identifying high risk patients. J Neuropsychiatry Clin Neurosci 1992;4:145–51
34. SchifferR B, WinemanM, WeitkampL R. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry 1986;143:94–5
35. MindenS L, OravJ, SchildkrautJ J. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology 1988;38:1631–4
36. ReischiesF M, BaumK, BräuH, HeddeJ P, SchwindtG. Cerebral magnetic resonance imaging findings in multiple sclerosis: relation to disturbance of affect, drive and cognition. Arch Neurol 1988;45:1114–16
37. FeinsteinA, du BoulayG, RonM A. Psychotic illness in multiple sclerosis: a clinical and magnetic resonance imaging study. Br J Psychiatry 1992;161:680–5
38. CottrellS S, WilsonS A K. The affective symptomatology of disseminated sclerosis. J Neurol Psychopath 1926;7:1–30
39. RabinsP V. Euphoria in multiple sclerosis. In: RaoS M, ed. Neurobehavioral aspects of multiple sclerosis. New York: Oxford University Press, 1990:180–5
40. FishmanI, BenedictR H B, BakshiR, PrioreR, Weinstock-GuttmanB. Construct validity and frequency of euphoria sclerotica in multiple sclerosis. J Neuropsychiatry Clin Neurosci 2004;16:350–6
41. Diaz-OlavarrietaC, CummingsJ L, VelasquezJ, Garcia de la Cadena C. Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin Neurosci 1999;11:51–7
42. RabinsP V, BrooksB R, O'DonnellO P, et al. Structural brain correlates of emotional disorder in multiple sclerosis. Brain 1986;109:585–97
43. RonM A, LogsdailS J. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med 1989;19:887–95
44. CummingsJ L, ArcinegasD B, BrooksB R, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Specr 2006;11:1–7
45. FeinsteinA, FeinsteinK J, GrayT, O'ConnorP. The prevalence and neurobehavioral correlates of pathological laughter and crying in multiple sclerosis. Arch Neurol 1997;54:1116–21
46. FeinsteinA, O'ConnorP, GrayT, FeinsteinK. Pathological laughing and crying in multiple sclerosis: a preliminary report suggesting a role for the prefrontal cortex. Mult Scler 1999;5:69–73
47. GhaffarO, ChamelianL, FeinsteinA. Neuroanatomy of pseudobulbar affect: a quantitative MRI study in multiple sclerosis. J Neurol 2008;255:406–12
48. SakheimH A, GreenbergM S, WeinmanA L, et al. Hemisphere asymmetry in the expression of positive and negative emotions. Arch Neurol 1982;39:210–18
49. SchifferR B, HerndonR M, RudickR A. Treatment of pathologic laughing and weeping with amitriptyline. New Engl J Med 1985;312:1480–2
50. SeligerG M, HornsteinA, FlaxJ, HerbertJ, SchroderK. Fluoxetine improves emotional incontinence. Brain Inj 1992;6:267–70
51. UdakaF, YamaoS, NagataH, NakamuraS, KameyamaM. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984;41:1095–6
52. PanitchH S, ThistedR A, SmithR A, et al. Randomized controlled trial of dextromethorphan/quinidine for pseudobulbar effect in multiple sclerosis. Ann Neurol 2006;59:780–7
53. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005;11:328–37
